Xia Binbin, Zheng Li, Li Yali, Sun Wenfang, Liu Yang, Li Liushui, Pang Jingyao, Chen Jing, Li Jiaxin, Cheng Hua
Department of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China.
Department of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, China.
Front Pharmacol. 2023 Jul 31;14:1098972. doi: 10.3389/fphar.2023.1098972. eCollection 2023.
To effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an increasing number of researchers are focusing on the antiviral activity of cepharanthine (CEP), which is a clinically approved drug being used for over 70 years. This review aims to provide a brief overview of CEP and summarize its recent findings in quantitative analysis, pharmacokinetics, therapeutic potential, and mechanism in antiviral and anti-SARS-CoV-2 activity. Given its remarkable capacity against SARS-CoV-2 infection and , with its primary target organ being the lungs, and its good pharmacokinetic profile; mature and stable manufacturing technique; and its advantages of safety, effectiveness, and accessibility, CEP has become a promising drug candidate for treating COVID-19 despite being an old drug.
为有效应对严重急性呼吸综合征冠状病毒2（SARS-CoV-2），越来越多的研究人员将重点放在了千金藤素（CEP）的抗病毒活性上，CEP是一种已临床批准使用70多年的药物。本综述旨在简要介绍CEP，并总结其在定量分析、药代动力学、治疗潜力以及抗病毒和抗SARS-CoV-2活性机制方面的最新研究结果。鉴于其对SARS-CoV-2感染具有显著的抑制能力，主要靶器官为肺，药代动力学特征良好，生产技术成熟稳定，且具有安全、有效、可及的优势，尽管是一种老药，但CEP已成为治疗新冠肺炎的一种有前景的候选药物。
